多股漲停！生物疫苗板塊集體爆發，中國新冠疫苗臨牀試驗傳佳報
17日生物疫苗板塊開盤大漲，截止發稿，西藏藥業、康華生物漲停，達安基因、鵬鷂環保漲超6%，博暉創新、未名醫藥、華北製藥等跟漲。
來源：同花順
消息面上，16日國藥中國生物武漢生物製品研究所研製的新冠病毒滅活疫苗Ⅰ/Ⅱ期臨牀試驗盲態審核暨階段性揭盲會在北京、河南兩地同步舉行。
試驗結果顯示疫苗接種後安全有效，接種疫苗組受試者均產生高滴度抗體，其中18-59歲組中劑量按照0,14天和0,21天程序接種兩劑後中和抗體陽轉率達97.6%，按照0,28天程序接種兩劑中和抗體陽轉率達100%。
按照一般規律，疫苗臨牀試驗一般分為三期，專家預計，如果中國生物Ⅲ期臨牀試驗理想，新冠生物疫苗預計最快的時間為今年底或明年初能夠上市。根據國藥集團此前公告，國藥集團旗下北京生物和武漢生物分別建設疫苗生產車間。其中，北京生物已於4月15日完成車間建設，武漢生物新冠滅活疫苗車間建設預計將在本月底或7月初完成，兩個研究所合計年產能將可達2億劑以上。
目前，我國新冠疫苗研發共分五條路線，包括滅活疫苗、腺病毒載體疫苗、重組蛋白疫苗、減毒流感病毒載體疫苗以及核酸疫苗，並且已有6種疫苗在臨牀試驗。
來源：興業證券
受消息影響，武漢生物製品研究所有股權關係的相關概念股中，國藥股份漲停，現代製藥漲超8%，天壇生物、國藥一致、衞光生物分別上漲6.27%、5.66%、1.59%。
來源：富途
據天眼查，武漢生物製品研究所由中國生物全資持股，而中國生物的大股東為國藥集團，持股比例為95%。國藥集團旗下有現代製藥、國藥股份等多家上市公司。除此之外，武漢生物製品研究所還持有A股上市公司衞光生物7.25%的股權；中國生物技術則持有A股公司天壇生物49.96%的股權。
今日漲停股中西藏藥業近日拿下斯微生物新冠疫苗獨家授權，後者在1月與中國疾病預防控制中心和同濟大學附屬東方醫院合作開展新冠mRNA疫苗研發項目，近期將開展臨牀試驗。公司股價自5月底開啟上漲通道，至今累計漲幅超過160%。
來源：同花順
此外，康泰生物、華蘭生物等本身是在研究新冠疫苗的公司；冠昊生物則與美國參股公司合作開展新型肺炎冠狀病毒mRNA疫苗的研究和臨牀項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
